How does a COVID-19 pill behave in the body? A small study in healthy men offers clues.

Before a drug can be used widely, researchers need to know how it's absorbed, how long it lasts, and if it's safe at the intended dose. This is the goal of a Phase 1 study, which is exactly what scientists did with the antiviral molnupiravir in a group of 16 healthy Chinese men. They gave the men the standard 800 mg dose used for COVID-19, both as a single dose and twice a day for five and a half days. They tracked the drug's active component, called NHC, in the blood. They found it reached its peak level about two hours after a dose, and its levels in the body didn't increase or 'accumulate' when people took it repeatedly—a good sign that the standard dosing schedule is appropriate. The drug was generally well-tolerated, though nearly two-thirds of the men experienced at least one side effect, all of which were mild or moderate, like a headache or feeling tired. No one had to stop taking it because of these effects. When compared to historical data from non-Asian participants, the drug's levels were slightly higher in these Chinese men, but still within an acceptable range. It's important to remember what this study is and isn't. It's a very early look in a small, specific group—only healthy young men. It tells us about the drug's basic behavior and safety in their bodies, but it doesn't test whether molnupiravir actually helps people fight off COVID-19. That's the critical question for larger, later-stage trials in people who are actually sick.